The mechanisms whereby the dendritic cells contribute to the development of psoriasis during the treatment of cancer patients with PD-1 inhibitors is based on the ability of tumor cells and tumor-infiltrating immune cells (e.g., macrophages and myeloid dendritic cells) to express PD-L1 [243,248]. Here, PDCD1 is linked to neoplasm.